Skip to main content
Fig. 1 | Harm Reduction Journal

Fig. 1

From: Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder

Fig. 1

Phase 3 study design. After screening, participants entered an open-label run-in phase of up to 2 weeks of treatment with buprenorphine/naloxone sublingual film (induction and stabilization), to achieve daily doses ranging from 8 mg/2 mg to 24 mg/6 mg. After run-in, Eligible participants were then randomly assigned (4:4:1:1) to receive BUP-XR 300 mg/300 mg, BUP-XR 300 mg/100 mg, or volume-matched placebo

Back to article page

Harm Reduction Journal

ISSN: 1477-7517